ADGRF5 and colorectal carcinoma: As shown in Figure 5A,B, higher expression of ADGRF5 was accompanied by a worse probability of OS and DFS in CRC patients, which was confirmed by HR = 1.51 (p < 0.01) and HR = 1.49 (p < 0.01) for CRC patients, respectively.